SCHEMBL4324653

SCHEMBL4324653

CCOCc1nc2cnc3cccnc3c2n1CCCCSCC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TLR8 Q9NR97 6/20 0.35
TLR7 Q9NYK1 7/20 0.35
NUDT1 P36639 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4324733 0.88 ENPP2 (0.37) KDM4EALDH1A1SMN1; SMN2HSD17B10TLR8
SCHEMBL4308944 0.87 TLR8 (0.42) TLR8TLR7NUDT1MEN1KMT2A
SCHEMBL4324657 0.87 HDAC4 (0.37) SMN1; SMN2TLR8TLR7NUDT1MEN1
SCHEMBL5617025 0.87 TLR8 (0.38) ALDH1A1TLR8TLR7NUDT1MEN1
SCHEMBL4314464 0.86 TLR8 (0.42) TLR8TLR7NUDT1MEN1KMT2A
SCHEMBL5617287 0.83 TLR7 (0.38) SMN1; SMN2TLR8TLR7NUDT1MEN1
SCHEMBL5617162 0.83 TLR8 (0.39) SMN1; SMN2TLR8TLR7NUDT1MEN1
SCHEMBL4793561 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2TLR8TLR7NUDT1
SCHEMBL4310319 0.83 TLR8 (0.39) ALDH1A1SMN1; SMN2TLR8TLR7NUDT1
SCHEMBL5616310 0.83 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2TLR8TLR7NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735421-B2 Imidazoquinolinyl sulfonamides 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-05-27 US disclosed
US-20090062272-A1 IMIDAZOQUINOLINYL SULFONAMIDES 3M INNOVATIVE PROPERTIES COMPANY 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062272-A1 IMIDAZOQUINOLINYL SULFONAMIDES IL2, EIF2AK2, IFNG KDM4E 4260/4885ALDH1A1 2828/4885SMN1; SMN2 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.